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wedge pressure (9 ± 2 vs. 8 ± 1, p = 0.001) in UCTD-risk-
SSc patients as compared to controls. Notably, a statistically 
significant difference also emerged in the prevalence of TDI 
detected E′/A′t, (71% of UCTD-risk-SSc patients vs. 19% of 
controls; p < 0.0001). Our study shows that UCTD-risk-SSc 
patients show a previously unrecognized, mild biventricular 
systolic and diastolic dysfunction as compared to controls. 
The pathophysiologic meaning as well the predictive value 
of developing overt SSc await to be elucidated.
Keywords Undifferentiated connective tissue disease 
at risk for systemic sclerosis · Very early–early systemic 
sclerosis · Heart in UCTD-risk-SSc · Cardiac involvement 
in SSc
Introduction
The label “undifferentiated connective tissue disease at risk 
for systemic sclerosis” (UCTD-risk-SSc) refers to a group 
of conditions characterized by Raynaud’s phenomenon 
(RP) with SSc marker autoantibodies and/or typical cap-
illaroscopic findings and unsatisfying 2013 ACR/EULAR 
classification criteria for SSc as well as criteria for SSc sine 
scleroderma [1]. These conditions are otherwise referred to 
as very early/early SSc [2–10]. The previously undefined 
boundaries with respect to other SSc stages [3, 7, 8] and the 
absence of a certain evolution into overt SSc [2, 8] induced 
us to first underline classification criteria [9] and then pro-
pose the change in the label [10].
Patients with UCTD-risk-SSc/early SSc have been 
reported to present, in about 40% of the patients, a preclini-
cal, vascular, internal organ disease as detected by a diffus-
ing lung capacity for CO (DLCO) < 80% of the predicted 
value (lung involvement) and/or a low oesophageal sphincter 
Abstract Undifferentiated connective tissue disease at risk 
for systemic sclerosis (UCTD-risk-SSc), otherwise referred 
to as very early–early SSc, is a condition characterized by 
Raynaud’s phenomenon with serum SSc marker autoanti-
bodies and/or typical capillaroscopic findings and unsatis-
fying classification criteria for the disease. The aim of the 
present study was to assess the prevalence of right (RV) or 
left ventricular (LV) systolic and/or diastolic dysfunction 
by standard echocardiography and tissue Doppler imaging 
(TDI). Thirty patients with UCTD-risk-SSc (28 female, 
mean age 47 ± 13 years, range 21–70) and 30 age- and sex-
matched controls underwent cardiac assessment by standard 
echocardiography and TDI. UCTD-risk-SSc patients and 
controls did not show any difference at standard echocardi-
ography. Despite results falling within the respective normal 
ranges, TDI pointed out a mild impairment of LV and RV 
diastolic (Em 15 ± 4 vs. 19 ± 5, p = 0.0004; E/Em 6.1 ± 1.7 
vs. 4.8 ± 1.2, p = 0.001; Et 14 ± 3 vs. 16 ± 2, p = 0.02; 
Et/At 0.9 ± 0.4 vs. 1.3 ± 0.3, p = 0.002; E/Et 3.5 ± 1.2 
vs. 4.2 ± 0.9, p = 0.02) and systolic function (Sm 13 ± 3 
vs. 15 ± 2 cm/s, p < 0.0003; St 14 ± 2 vs. 16 ± 3 cm/s, 
p < 0.0001) and increased estimated pulmonary artery 
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(LES) pressure < 15 mmHg (oesophageal involvement) and/
or a mitral E/A ratio < 1 (heart involvement) [2, 6, 8]. How-
ever, the prevalence of the latter finding did not result to 
differ between patients and controls.
Pulsed tissue Doppler imaging (TDI) is a non-invasive 
technique introduced after standard echocardiography and 
widely available at present. It allows to detect early right 
and left heart functional abnormalities with higher sensi-
tivity and specificity than standard echocardiography [11, 
12]. Actually, investigating 74 definite SSc patients by both 
standard echocardiography and pulsed TDI, we could detect 
a greater prevalence of systolic and diastolic dysfunction 
by the latter technique and a further deterioration of both at 
3 years of follow-up [13].
The aim of the present study is to assess the prevalence of 
right (RV) or left ventricular (LV) diastolic and/or systolic 
dysfunction by both standard echocardiography and TDI in 
UCTD-risk-SSc patients.
Materials and methods
Thirty patients with UCTD-SSc-risk, consecutively admit-
ted from 1 June 2015 to 31 May 2016 at the Rheumatol-
ogy Unit of the University of Campania “Luigi Vanvitelli” 
(28 female, aged 21–70 years, mean 47 ± 13 years, median 
47.5 years), were enrolled in the study after giving written 
informed consent.
Classification
UCTD-SSc-risk was diagnosed in patients with RP and 
either SSc marker autoantibodies or distinct capillaroscopic 
alterations, who at admission neither satisfied the 2013 
ACR/EULAR criteria for SSc [14] nor presented any mani-
festation suggestive of SSc sine scleroderma [15].
Assessment at admission
Patients underwent a detailed history, an accurate physi-
cal examination, routine laboratory investigations, nailfold 
capillaroscopy, autoantibody detection and investigation of 
preclinical organ involvement, as previously described [4]. 
Patients were investigated for typical microvascular altera-
tions (megacapillaries and/or avascular areas) by wide-
field nailfold capillary microscopy, ANA and SSc marker 
autoantibodies (i.e. anti-DNA topoisomerase I-anti-Scl70; 
anticentromere-ACA; anti-RNA polymerase III; anti-fibril-
larin; anti-Pm-Scl; and anti-Th/To), as previously described 
[4–6, 9].
Medications
All the 30 patients were being treated with acetylsalicylic 
acid and dihydropyridine calcium channel blockers. Two 
out of them had arterial hypertension: one was also being 
treated with ACE-inhibitors, the other one with angiotensin 
receptor blockers.
Controls Thirty age- and sex-matched controls (28 female, 
aged 18–68 years; mean 46 ± 12 years, median 46.5 years) 
admitted to the Outpatient Clinic of the Cardiology Unit, 
who presented no relevant findings at clinical examination, 
ECG and chest radiography and denied any acrovascular 
symptoms, were enrolled in the study after giving written 
informed consent. Six out them had arterial hypertension: 
three were being treated with dihydropyridine calcium 
channel blockers, two with ACE-inhibitors and one with a 
combination of the two drugs.
Preclinical internal organ involvement
Lung and oesophagus
All the patients underwent lung function study according to 
established guidelines [16] to investigate DLCO, whereas 
only patients who consented were investigated by oesopha-
geal manometry [17] devoted to assess basal LES pressure.
Echocardiography
Echocardiographic examinations were performed by two 
independent highly trained cardiologists (PA and ER), 
blinded to the clinical characteristics of the study population, 
using commercially available equipment with a phased array 
system (Vivid E9, GE Healthcare, Milwaukee, Wisconsin, 
USA) and a 2.5- or 3.5-MHz transducer.
The procedure was performed following international 
recommendations [18].
Specific views included the parasternal long- and short-
axis views (at the mitral valve and papillary muscle level), 
apical four-, two- and three-chamber views and subcostal 
views, including respiratory motion of the inferior cava vein. 
Pulsed, continuous wave and colour-Doppler interrogation 
was performed on all four cardiac valves. TDI analysis was 
performed for analysing diastolic and systolic function of 
both left and right ventricles from the four-chamber view. 
Specific measurements were made by the average of 3–5 
cardiac cycles.
M‑ and  B‑mode measurements LV diastolic and sys-
tolic diameters, interventricular septum and posterior wall 
thickness were assessed in parasternal long-axis view with 
the patient in the left lateral position. LV ejection frac-
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tion was calculated by the biplane Simpson’s rule in the 
apical four- and two-chamber views. Left atrial maximal 
volume was measured at the point of mitral valve opening 
using the biplane area–length method and corrected for 
body surface area [18]. RV end-diastolic chamber size was 
accurately assessed using five linear dimensions according 
to the American Society of Echocardiography guidelines 
for the echocardiographic assessment of the right heart 
in adults [18]. In particular, three of the five parameters 
included the measurement of the basal, mid-cavity and 
longitudinal diameters from the apical four-chamber view 
at end-diastole. The echotransducer was adjusted to the 
level of the RV chamber, with the goal of optimizing RV 
chamber size. The remaining two parameters included the 
measurement of the RV outflow tract at the proximal or 
subpulmonary region and at the distal or pulmonic valve 
from the basal parasternal short axis and the parasternal 
short axis of pulmonary bifurcation views, respectively. 
Right atrial (RA) measurements were assessed in the api-
cal four-chamber view. RA area was estimated by plani-
metry at the end of ventricular systole (largest volume), 
tracing from the lateral aspect of the tricuspid annulus to 
the septal aspect, excluding the area between the leaflets 
and annulus, following the RA endocardium, excluding 
the inferior and superior cava vein and RA appendage 
[18]. Tricuspid annular plane systolic excursion (TAPSE) 
was calculated as index of RV longitudinal systolic func-
tion by placing an M-mode cursor through the tricuspid 
annulus in a standard apical four-chamber window, and 
measuring the difference between the end-diastolic and 
end-systolic amount of longitudinal motion of the annu-
lus.
Colour‑Doppler analysis Valve regurgitation was quanti-
fied from colour-Doppler imaging. Intermediate vena con-
tracta values (3–7  mm) were confirmed by the proximal 
isovelocity surface area method [18].
Pulsed wave Doppler-derived LV and RV diastolic inflow 
was recorded in the apical four-chamber view by placing the 
sample volume at the tip level of the mitral and tricuspid 
valves. E and A peak velocities (m/s) and their ratio were 
measured for both ventricles [18].
Tissue Doppler imaging In order to obtain a measure of 
LV and RV myocardial function by TDI, LV and RV peak 
systolic velocity (S′m and S′t, respectively) and LV and RV 
early and late diastolic velocity (E′m, A′m, E′t, A′t, respec-
tively) were assessed from the apical four-chamber view by 
placing the sample volume at the mitral and tricuspid annu-
lus. The E′m considered was the mean value from the lateral 
and medial position. Because this technique uses Doppler, 
special care is required to ensure optimal image orientation 
and avoid underestimation of velocities.
Non‑invasive pulmonary artery systolic pressure Peak 
tricuspid regurgitant velocity was measured from the spec-
tral profile of the tricuspid regurgitant jet in the RV inflow 
projection of the parasternal long-axis view, the parasternal 
short-axis view or the apical four-chamber view. The high-
est transvalvular velocity was used for calculation of right 
ventricular systolic pressure. Pulmonary artery systolic 
pressure (sPAP) was assumed to equate right ventricular 
systolic pressure in the absence of pulmonic stenosis and/
or RV outflow tract obstruction. sPAP was then calculated 
as 4 × V2 + estimated RA pressure by inferior vena cava 
dimension and collapsibility [18] (where V is the maximal 
velocity of the tricuspid regurgitant jet). Mean pulmonary 
artery pressure was calculated as 0.6 × sPAP + 2 [18]. Cap-
illary wedge pressure (CWP) was estimated from the ratio 
of mitral E flow velocity wave and tissue Doppler mitral 
annulus E′ early diastolic velocity, with CWP = 1.9 + 1.24 
E/E′m [19].
All data were analysed offline by two observers blinded 
to the patient conditions (MD and AD). Intra- and inter-
observer variability was less than 1% and less than 4.0%, 
respectively.
Statistical analysis
Continuous variables were analysed by paired and unpaired 
t test. Chi-square test or Fisher exact test was applied for 
contingency tables. Spearman’s rank order correlation test 
was used to investigate associations between distinct con-
tinuous variables. Covariate-adjusted analysis of outcome 
was performed by Cox proportional hazards model.
A p value < 0.05 was considered statistically significant. 
Data are expressed as mean ± SD. Statistical analysis was 
performed using SPSS software on PC (version 12.0.1; 
SPSS Inc., Chicago, Illinois, USA).
Results
Table 1 lists demographic, serological, capillaroscopic, 
subsetting and therapeutic data of the 30 UCTD-risk-SSc 
patients enrolled in the study. A preclinical lung involve-
ment was detected in 12 patients, a preclinical oesophageal 
involvement was observed in six patients, out of whom three 
had a DLCO < 80%. Therefore, 15 patients (50%) showed 
either lung or oesophageal preclinical internal organ involve-
ment, or both.
Table 2 shows the main standard echocardiographic and 
TDI parameters recorded in the study population. No dif-
ference was detected between UCTD-risk-SSc patients and 
controls in any standard mono- and 2D echocardiography-
detected parameter. TDI revealed a significantly reduced 
Em wave suggestive of impaired LV diastolic function; 
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significantly reduced Et, increased At and reduced Et/At 
ratio, each suggestive of impaired RV diastolic function; 
and significantly reduced Sm and St suggestive of LV and 
RV involvement, respectively. In addition, pulmonary 
artery wedge pressure (PAWP), generically indicative of 
left heart disease, was found to be increased (9 ± 2 vs. 
8 ± 1, p = 0.001). Nevertheless, no difference was detected 
in estimated sPAP (29 ± 3 vs. 27 ± 3, p = 0.13), nor in 
SV (data not shown). In this regard, it is worth noting that 
neither SSc patients nor any controls showed any signifi-
cant mitral or aortic valve regurgitation or stenosis, and 
neither UCTD-risk-SSc patients nor controls had pericar-
dial effusion.
Table 3 lists the prevalence of definitely altered systolic 
and diastolic function of right and left ventricles by conven-
tional Doppler echocardiography and TDI. We detected a 
greater prevalence of mitral E/A < 1 (33 vs. 23%), E′/A′m < 1 
(42 vs. 29%) and Et/At < 1 (20 vs. 10%). Nevertheless, a sta-
tistically significant difference only emerged in TDI detected 
E′/A′t, which was found to be < 1 in 71% of UCTD-risk-SSc 
patients versus 19% of controls (p < 0.0001).
As far as the relationships between distinct TDI param-
eters, LV and RV diastolic and systolic function resulted to 
be nearly significantly related each other: rho between E′/A′t 
and E′/A′m being 0.35 (p = 0.006) and that between St and 
Sm 0.47 (p = 0.008). These results are consistent with SSc 
myocardial disease where small intramyocardial coronary 
vessels and fibrosis involve both ventricles.
No significant association emerged between any TDI 
parameter and either autoantibody profile or the presence 
of lung and/or oesophageal preclinical involvement.
Discussion
Preclinical internal organ involvement in patients with 
UCTD-risk-SSc/very early–early SSc was first reported by 
us in 2011, demonstrating the presence of a DLCO < 80% 
Table 1  Demographic, serological, capillaroscopic and physiological 
features of the 30 UCTD-risk-SSc/early SSc patients enrolled in the 
study
DLCO diffusing lung capacity for CO, LES low oesophageal sphinc-
ter, RP Raynaud’s phenomenon, SSc systemic sclerosis, UCTD‑risk‑
SSc undifferentiated connective tissue disease at risk for systemic 
sclerosis
Sex (F/M) 28/2
Age (years) Median 47.5; range 21–70
Disease duration from RP onset (years) Median 7; range 0–24
Antinuclear antibodies 27 (90%)
Marker SSc antibody 20 (66%)
 Anticentromere 13 (43%)
 Anti-DNA topoisomerase I 6 (20%)
 Anti-RNA polymerase III 0
 Anti-fibrillarin 0
 Anti-Th/To 0
 Anti-Pm-Scl 1 (3%)
Capillaroscopic findings
 Avascularar areas ± megacapillaries 0
 Megacapillaries only 22 (73%)
Preclinical internal organ involvement (lung and oesophagus)
 Basal LES pressure < 15 mmHg 6/20 (30%)
 DLCO < 80% of the predicted value 12/30 (40%)
 Any of them 15/30 (50%)
Table 2  Echocardiographic features in the study population
UCTD‑risk‑SSc undifferentiated connective tissue disease at risk for 
systemic sclerosis, LVEDd left ventricular end-diastolic diameter, 
LVESd left ventricular end-systolic diameter, IVS interventricular 
septum, PW posterior wall, LVEF left ventricular ejection fraction, 
TAPSE tricuspid annulus plane systolic excursion, ICV inferior cava 
vein, LA left atrium, E E wave, A A wave, Sm S wave at mitral annu-
lus, Em E wave at mitral annulus, Am A wave at mitral annulus, St S 
wave at tricuspid annulus, Et E wave at tricuspid annulus, At A wave 
at tricuspid annulus
UCTD-
risk-SSc 
(n = 30)
Controls (n = 30) p
Mono and 2D
 LVEDd (mm) 46 ± 5 46 ± 2 0.55
 LVESd (mm) 28 ± 4 29 ± 2 0.14
 IVS (mm) 10 ± 3 10 ± 2 0.59
 PW (mm) 9 ± 3 8 ± 3 0.20
 LVEF (%) 61 ± 4 63 ± 4 0.11
 TAPSE (mm) 23 ± 3 22 ± 4 0.13
 ICV (mm) 13 ± 4 14 ± 3 0.38
 LA area index (ml/m2) 23 ± 5 22 ± 4 0.67
Doppler left heart
 Em (cm/s) 85 ± 17 88 ± 11 0.41
 Am (cm/s) 73 ± 17 70 ± 13 0.49
 Em/Am 1.2 ± 0.4 1.3 ± 0.3 0.22
 E′m (cm/s) 15 ± 4 19 ± 5 0.0004
 A′m (cm/s) 12 ± 4 13 ± 4 0.21
 E′/A′m 1.5 ± 0.7 1.6 ± 0.5 0.42
 E/E′m 6.1 ± 1.7 4.2 ± 1.2 0.002
 Sm (cm/s) 13 ± 3 15 ± 2 0.0003
Doppler right heart
 Et (cm/s) 59 ± 12 56 ± 14 0.45
 At (cm/s) 47 ± 15 42 ± 8 0.08
 E/At 1.3 ± 0.4 1.3 ± 0.2 0.73
 E/E′t 4.2 ± 0.9 3.5 ± 1.2 <0.02
 E′t (cm/s) 14 ± 3 16 ± 2 0.02
 A′t (cm/s) 17 ± 5 13 ± 3 0.001
 E′/A′t 0.9 ± 0.4 1.3 ± 0.3 0.002
 St (cm/s) 14 ± 2 16 ± 3 <0.0001
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of the predicted value, a basal LES pressure < 15 mmHg 
and an inverted E/A ratio in seven, four and one patients, 
respectively, accounting for a cumulative prevalence of 8/19 
patients (42%) [4]. Subsequently, we confirmed these results 
on a larger series [6, 9]. Moreover, Lepri et al. [8], while 
confirming the occurrence of a low basal LES pressure, 
pointed out the presence of impaired anorectal function in a 
separate single-centre study.
Out of the distinct findings of preclinical internal organ 
involvement, the impaired LV filling as detected by an 
inverted mitral E/A ratio was the only parameter, the preva-
lence of which did not result to be statistically different from 
that of controls [4, 6, 9].
A number of studies have been devoted to investigate 
cardiac disease in patients with definite SSc by TDI [13, 
20–25], and all have ensued in the detection of a higher prev-
alence of both RV and LV diastolic and systolic alterations.
To the best of our knowledge, this is the first study that 
investigated cardiac disease in patients with UCTD-risk-SSc/
early SSc by pulsed TDI. We found significantly lower Em, 
Et, E/At and E/E′t and significantly higher At, all indicative 
of diastolic impairment of both ventricles, and significantly 
lower Sm and St indicative of systolic impairment as well. 
Moreover, a statistically significant difference emerged in 
the prevalence of TDI inverted E′/A′t, (71% of UCTD-risk-
SSc patients vs. 19% of controls; p < 0.0001).
Taken together, these results demonstrate the presence of 
preclinical heart disease in UCTD-risk-SSc patients, which 
could depend on small intramyocardial coronary involve-
ment and/or patchy myocardial fibrosis, which are the dis-
tinctive features of SSc heart disease [20, 21]. Preclinical 
heart disease was not found to be related either to autoanti-
body profile or preclinical lung or oesophageal involvement, 
mirroring definite SSc in which no distinct autoantibody 
profile is associated with heart disease and the involvement 
of different organ vascular trees are not associated each 
other.
From a pathophysiologic point of view, the contribution 
of each of the two mentioned alterations to the impaired 
diastolic and systolic function awaits to be investigated by a 
cardiac magnetic resonance [22] and/or an endomyocardial 
biopsy study [23].
Detecting patchy myocardial fibrosis in UCTD-risk-SSc/
early SSc patients, who, by definition, do not satisfy the 
2013 ACR/EULAR classification criteria for SSc [14], might 
pave the way to the need for an earlier detection of internal 
organ involvement in these patients. Unravelling this aspect 
might be instrumental in choosing the appropriate drugs to 
be administered to the individual UCTD-risk-SSc/early SSc 
patient in order to contrast the evolution of his/her heart 
disease.
At present, no study has definitely pointed out a role 
of any drug in the treatment of scleroderma heart disease. 
Allanore et al. [24] detected a lower prevalence of LV ejec-
tion fraction < 55% in SSc patients who were given calcium 
channel blockers. Lee et al. [25] reported a lower preva-
lence of LV diastolic impairment in SSc patients who had 
been treated with ACE-inhibitors. These drugs and recently 
available antifibrotic agents [26] might have a role in this 
scenario.
Out of the parameters of diastolic and systolic function, 
the distribution of which resulted to be statistically different 
between UCTD-risk-SSc/early SSc patients and controls, an 
E′/A′t < 1 only was found to be more prevalent in the former 
(71 vs. 19%; p < 0.0001). Although the topic is debated [27], 
our data appear to identify in an impaired, right ventricular 
diastolic filling the first, defined, altered physiologic param-
eter in UCTD-risk-SSc/early SSc.
Our team was the first to show the presence of RV dias-
tolic dysfunction in SSc patients, as assessed by standard 
echocardiography, which was associated with LV dysfunc-
tion and pulmonary artery pressure [28]. This finding was 
then confirmed by TDI examination [29]. Recently, RV 
diastolic dysfunction was observed in 25% out of 212 SSc 
patients and was found to be associated with pulmonary 
artery pressure [30]. In our series, RV and LV diastolic and 
systolic function was found to be related with each other as 
it would be expected by the known distribution of vascular 
and interstitial involvement in the SSc heart. However, an 
additive effect of increased pulmonary artery pressure is 
likely to occur.
Preclinical lung or heart involvement as evidenced by 
a DLCO < 80% of the predicted value and/or a mitral E/A 
ratio < 1 was found by us to be associated with a signifi-
cantly increased incidence of defined SSc during follow-up 
in 60 well-characterized early SSc patients (who were sub-
sequently labelled as UCTD-risk-SSc) [9]. A prospective 
Table 3  Prevalence of parameters suggestive of altered left and right 
ventricular diastolic and systolic function by standard Doppler echo-
cardiography and tissue Doppler imaging in the study population
Values are expressed as number (%)
UCTD‑risk‑SSc undifferentiated connective tissue disease at risk for 
systemic sclerosis, E E wave, A A wave, E′m E wave at mitral annulus, 
A′m A wave at mitral annulus, E′t E wave at tricuspid annulus, A′t A 
wave at tricuspid annulus, Sm S wave at mitral annulus, St S wave at 
tricuspid annulus
UCTD-risk- 
SSc (n = 30)
Controls (n = 30) p
E/Am < 1 (%) 10 (33) 7 (23) 0.56
E′/A′m < 1 (%) 13 (42) 9 (29) 0.42
E/At < 1 (%) 6 (20) 3 (10) 0.47
E′/A′t < 1 (%) 22 (71) 6 (19) <0.0001
Sm < 7.5 cm/s (%) 0 (0) 0 (0) 1
St < 11.5 cm/s (%) 2 (6) 1 (3) 1
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study is needed to ascertain whether alterations detected 
by TDI have an additive prognostic value.
The detection of preclinical lung and/or oesophageal 
and/or cardiac involvement could induce to consider 
UCTD-risk-SSc patients or at least those with such physi-
ologic alterations, as SSc patients unsatisfying classifica-
tion criteria [14, 15]. Nonetheless, the same, putatively 
vascular, lung, oesophageal and standard echocardiogra-
phy alterations are also detectable in patients with strictly 
defined UCTD [4, 5], including, as far as lung involve-
ment is concerned, patients without Raynaud’s phenom-
enon [31]. These considerations, along with the lack of a 
certain evolution into defined SSc, underlie the view that 
what really separates SSc from UCTD-risk-SSc (or early 
SSc) is the presence of skin or organ fibrosis [1] and sup-
port the use of the current terminology, i.e. UCTD-risk-
SSc or early SSc.
Our study has two main limitations: we did not per-
form 2D strain imaging, which represents an additional 
and novel tool for an early identification of systolic and 
diastolic dysfunction; the present study is a single-centre 
study with a small number of patients. Further larger and 
multicentre studies are warranted to confirm our data.
In conclusion, despite echoparameters fall in the normal 
range, our data raise interesting question marks regard-
ing the heart function suggesting the presence of a subtle 
diastolic and systolic alterations of RV and LV function in 
patients with UCTD-risk-SSc/early SSc.
From a nosographic point of view, our results widen the 
boundaries of the preclinical, internal organ involvement 
in these conditions.
From a pathophysiologic point of view, our results sug-
gest the presence of an early heart involvement in patients 
who have a 50% risk of developing overt SSc, but do not 
yet satisfy the classification criteria for SSc. Unravelling 
the cause of these alterations (i.e. whether they depend on 
small intramyocardial coronary artery disease or patchy 
fibrosis, or any of them) is likely to contribute to the 
understanding of the pathogenesis of SSc heart disease.
From a clinical point of view, TDI emerges as the 
technique to be used in the approach to the patient with 
UCTD-risk-SSc/early SSc in order to highlight the pres-
ence of alterations that would be missed by using standard 
echocardiography only.
From a therapeutic perspective, the characterization of 
the anatomical alterations underlying these physiologic 
alterations is likely to assist in preventing the evolution of 
heart disease in these patients.
Compliance with ethical standards 
Conflict of interest The authors declare that they have no conflicts 
of interest.
Ethical approval The study was approved by Ethical Committee 
of University of Campania “Luigi Vanvitelli” (protocol number 709).
Informed consent Informed consent was obtained from all indi-
vidual participants included in the study.
References
 1. Valentini G. Undifferentiated connective tissue disease at risk for 
systemic sclerosis (SSc) (so far referred to as very early/early SSc 
or pre-SSc). Autoimmun Rev. 2015;14:210–3.
 2. Koenig M, Joyal F, Fritzler MJ, et al. Autoantibodies and micro-
vascular damage are independent predictive factors for the pro-
gression of Raynaud’s phenomenon to systemic sclerosis: a 
twenty-year prospective study of 586 patients with validation of 
proposed criteria for early systemic sclerosis. Arthritis Rheum. 
2008;58:3902–12.
 3. Avouac J, Fransen J, Walker UA, et al. Preliminary criteria for 
the very early diagnosis of systemic sclerosis: results of a Delphi 
consensus study from EULAR Scleroderma Trials and Research 
group. Ann Rheum Dis. 2011;70:476–81.
 4. Valentini G, Cuomo G, Abignano G, et al. Early systemic scle-
rosis: assessment of clinical and pre-clinical organ involve-
ment in patients with different disease features. Rheumatology. 
2011;50:317–23.
 5. Valentini G, Vettori S, Cuomo G, et al. Early systemic sclerosis: 
short-term disease evolution and factors predicting the develop-
ment of new manifestations of organ involvement. Arthritis Res 
Ther. 2012;14:R188.
 6. Valentini G, Marcoccia A, Cuomo G, et al. Early systemic scle-
rosis: marker autoantibodies and videocapillaroscopy patterns 
are each associated with distinct clinical, functional and cellular 
activation markers. Arthritis Res Ther. 2013;15:R63.
 7. Minier T, Guiducci S, Bellando-Randone S, et  al. Prelimi-
nary analysis of the very early diagnosis of systemic sclerosis 
(VEDOSS) EUSTAR multicentre study: evidence for puffy fingers 
as a pivotal sign for suspicion of systemic sclerosis. Ann Rheum 
Dis. 2014;73:2087–93.
 8. Lepri G, Guiducci S, Bellando Randone S, et al. Evidence for 
oesophageal and anorectal involvement in very early systemic 
sclerosis (VEDOSS): report from a single VEDOSS/EUSTAR 
centre. Ann Rheum Dis. 2015;74:124–8.
 9. Valentini G, Marcoccia A, Cuomo G, et al. Early systemic sclero-
sis: analysis of the disease course in patients with marker autoan-
tibodies or capillaroscopic positivity or both. Arthritis Care Res. 
2014;66:1520–7.
 10. Valentini G, Marcoccia A, Cuomo G, Iudici M, Vettori S. The 
concept of early systemic sclerosis following 2013 ACR/EULAR 
criteria for the classification of systemic sclerosis. Curr Rheuma-
tol Rev. 2014;10:38–44.
 11. Nagueh SF, Middleton KJ, Kopelen HA, Zoghbi WA, Quiñones 
MA. Doppler tissue imaging: a noninvasive technique for evalu-
ation of left ventricular relaxation and estimation of filling pres-
sures. J Am Coll Cardiol. 1997;30:1527–33.
 12. Yu CM, Sanderson JE, Marvick TH, Oh JK. Tissue Doppler imag-
ing: a new prognosticator for cardiovascular diseases. J Am Coll 
Cardiol. 2007;49:1903–14.
 13. D’Alto M, Cuomo G, Romeo E, et al. Tissue Doppler imaging in 
systemic sclerosis: a 3-year longitudinal study. Semin Arthritis 
Rheum. 2014;43:673–80.
 14. Van den Hoogen F, Khanna D, Fransen J, et al. Classification crite-
ria for systemic sclerosis: an American College of Rheumatology/
Clin Exp Med 
1 3
European League against Rheumatism collaborative initiative. 
Arthritis Rheum. 2013;65:2737–47.
 15. Poormoghin H, Lucas M, Fertig N, Medsger TA Jr. Systemic 
sclerosis sine scleroderma: demographic, clinical, and serologic 
features and survival in forty-eight patients. Arthritis Rheum. 
2000;43:444–51.
 16. Ogilvie CM, Forster RE, Blakemore WS, Morton JW. A stand-
ardized breath holding technique for clinical measurement of the 
diffusing capacity of the lung for carbon monoxide. J Clin Invest. 
1957;15:1–17.
 17. del Genio G, Tolone S, del Genio F, et al. Prospective assessment 
of patient selection for antireflux surgery by combined multichan-
nel intraluminal impedance pH monitoring. J Gastrointest Surg. 
2008;12:1491–6.
 18. Lang RM, Badano LP, Mor-Avi V, et al. Recommendations for 
cardiac chamber quantification by echocardiography in adults: 
an update from the American Society of Echocardiography and 
the European Association of Cardiovascular Imaging. J Am Soc 
Echocardiogr. 2015;28(1):1–39.
 19. Nagueh SF, Smiseth OA, Appleton CP, et al. Recommendations 
for the evaluation of left ventricular diastolic function by echocar-
diography: an update from the American Society of Echocardiog-
raphy and the European Association of Cardiovascular Imaging. 
J Am Soc Echocardiogr. 2016;29(4):277–314.
 20. Kahan A, Allanore Y. Primary myocardial involvement in sys-
temic sclerosis. Rheumatology. 2006;45(Suppl 4):iv14–7.
 21. Parks JL, Taylor MH, Parks LP, Silver RM. Systemic sclerosis and 
the heart. Rheum Dis Clin North Am. 2014;40:87–102.
 22. Hachulla AL, Launay D, Gaxotte V, et al. Cardiac magnetic reso-
nance imaging in systemic sclerosis: a cross-sectional observa-
tional study of 52 patients. Ann Rheum Dis. 2009;68:1878–84.
 23. Mueller KA, Mueller II, Eppler D, et al. Clinical and histopatho-
logical features of patients with systemic sclerosis undergoing 
endomyocardial biopsy. PLoS ONE. 2015;10:e0126707.
 24. Allanore Y, Meune C, Vonk MC, et al. Prevalence and factors 
associated with left ventricular dysfunction in the EULAR Scle-
roderma Trial and Research group (EUSTAR) database of patients 
with systemic sclerosis. Ann Rheum Dis. 2010;69:218–21.
 25. Lee SW, Choi EY, Jung SY, Choi ST, Lee SK, Park YB. E/E′ ratio 
is more sensitive than E/A ratio for detection of left ventricular 
diastolic dysfunction in patients with systemic sclerosis. Clin Exp 
Rheumatol. 2010;28(Suppl 58):S12–7.
 26. Distler JH, Feghali-Bostwick C, Soare A, Asano Y, Distler O, 
Abraham DJ. Frontiers of antifibrotic therapy in systemic sclero-
sis. Arthritis Rheumatol. 2016;. doi:10.1002/art.39865.
 27. Meune C, Allanore Y. Abnormal right ventricular diastolic func-
tion may not be the only early marker of myocardial involvement 
in systemic sclerosis. Chest. 2006;130:302.
 28. Giunta A, Tirri E, Maione S, et al. Right ventricular diastolic 
abnormalities in systemic sclerosis. Relation to left ventricu-
lar involvement and pulmonary hypertension. Ann Rheum Dis. 
2000;59:94–8.
 29. Lindqvist P, Caidahl K, Neuman-Andersen G, et al. Disturbed 
right ventricular diastolic function in patients with systemic scle-
rosis: a Doppler tissue imaging study. Chest. 2005;128:755–63.
 30. Meune C, Khanna D, Aboulhosn J, et al. A right ventricular dias-
tolic impairment is common in systemic sclerosis and is asso-
ciated with other target-organ damage. Semin Arthritis Rheum. 
2016;45:439–45.
 31. Riccardi A, Irace R, Di Stefano I, et al. Lung involvement in “sta-
ble” undifferentiated connective tissue diseases: a rheumatology 
perspective. Clin Rheumatol. 2017;36:1833–7.
